🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

@US_FDAMedicalImaging Drugs #AdCom voted benefits of our investigational optical imaging agent LUMISIGHT™ outweighed potential risks and can provide surgeons an additional tool to aid in real-time surgical detection of residual cancer during lumpectomy bit.ly/3T7ThEG

Sharing highlights from intraoperative fluorescence-guided imaging research showcased at the Society of Surgical Oncology (SSO) 2024 Annual meeting. Read our release here. businesswire.com/news/home/2024…

BREAKING NEWS:  LUMISIGHT™ and Lumicell™ DVS are FDA-approved, and together are referred to as LumiSystem™. With 84% diagnostic accuracy, LumiSystem enables surgeons to scan the breast cavity post-lumpectomy, in real-time, to detect and resect residual cancer that may have

The American Medical Association has granted Lumicell a Category III, Current Procedural Terminology (CPT) add-on code 0945T specifically for intraoperative fluorescence imaging margin assessment following breast cancer lumpectomy. The new CPT code is expected to become effective

A new transitional pass-through payment code for LUMISIGHT™ (pegulicianine) has been granted to Lumicell™! This will increase patient access to our new innovative technology, LumiSystem™, that helps surgeons find breast cancer during surgery that might otherwise go

We've been awarded an NIH @NCIPhase 1 SBIR contract to develop a novel endoscope to be used with LUMISIGHT™ (peguliciane) for the detection of early esophageal lesions in patients with Barrett’s Esophagus. We're excited to further explore the potential of our fluorescence

In the United States, 1 in 8 women will develop breast cancer in their lifetime. Lumicell is on a mission to transform breast cancer surgery. No one should face breast cancer alone. #BreastCancerAwareness #bcam

For patients who have breast cancer, the reality is that achieving negative margins often proves difficult. Up to 36% of patients who have a lumpectomy surgery may need a second surgery after their initial surgery showed positive margins.[1] The news of a second surgery can be

We are excited to share that during this Breast Cancer Awareness Month, Viewpoint with Dennis Quaid has featured Lumicell's cutting-edge technology. To watch the video, click the following link and then press the 'play' button: viewpointproject.com/features-posti… To learn more, visit

The Lumicell team and their families participated in the 2024 Susan G. Komen walk to support the mission of ending breast cancer and the mission to improve access to quality breast cancer screening, diagnosis and treatment for all. #Lumicell #BreastCancerAwarenessMonth #BCAM

Lumicell is pleased to announce the appointment of Howard Hechler as Chief Executive Officer. “The Board of Directors unanimously voted to appoint Howard as Lumicell’s CEO, based upon the crucial role he played in leading Lumicell through our FDA-approval process and preparing

Lumicell™ has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code for Hospital Outpatient Prospective Payment System (OPPS) by the Centers for Medicare & Medicaid Services (CMS) for its innovative optical imaging agent, LUMISIGHT™ (pegulicianine),

At SABCS 2024, Lumicell presented new data focused on patient benefit of using LumiSystem™ during lumpectomy. The findings suggest that patient satisfaction with cosmetic outcomes did not change following fluorescence-guided tissue removal and showed a strong preference for

Lumicell is pleased to announce the appointment of Jim Alecxih to its Board of Directors. “We’re excited to welcome Jim to our Board of Directors. His extensive commercial and operational experience, along with a proven track record of success, will be invaluable to Lumicell,”

We are proud to announce the U.S. commercial availability and first clinical use of LumiSystem™, the first and only fluorescence-guided imaging technology used during surgery for detection of residual breast cancer. This innovative system represents a significant advancement in

Lumicell’s innovative surgical imaging technology has been featured in USA Today®. Learn more about this technology and visit LearnAboutLumicell.com. Read the full article here: usatoday.com/story/sponsor-… #BreastCancerAwareness #HealthcareInnovation #Lumicell #USATodayFeature

Lumicell has introduced LumiSystem to the #US, bringing real-time cancer detection to breast-conserving surgeries. 📖 Read more: eu1.hubs.ly/H0gr1V40 📩 Subscribe to our newsletter: eu1.hubs.ly/H0gr25W0 #CancerCare #S #PrecisionMedicine #MedTech #medTechWorld

With 84% diagnostic accuracy, LumiSystem™ improved surgical outcomes in 10% of patients treated in the INSITE pivotal trial.¹⁻² By identifying cancerous tissue that would have been missed, LumiSystem offers a more comprehensive approach to breast-conserving surgery and

Despite surgical advancements, up to 36% of patients require a second lumpectomy because cancer may have gone undetected.¹  However, when these second surgeries are performed, cancer is not found in up to 65% of cases.¹ This leaves patients and surgeons uncertain about the

Thank you, Dr. Andrew Chan and Dr. David Drew, for presenting our promising feasibility trial findings in gastrointestinal cancer patients at AACR 2025. Lumicell's imaging research was discussed during the Stand Up To Cancer (SU2C) open Scientific Session "Advances in Detection